# CaaMTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caamtech

- Industry: Pharmaceuticals
- Headquarters: Issaquah, US
- Website: www.caam.tech
- Total disclosed funding: $22M
- Latest round: Series A (Sep 8, 2021)
- Investors on record: 1

## About

Based in Washington, US, and founded in 2019, CaaMTech, Inc. develops and optimizes psychedelic compounds to build a patent portfolio. The company was founded by Dr. Andrew Chadeayne who was also a Chief Innovations Officer at ebb, Inc. In September 2021, the company raised its latest Series A led by Noetic Fund.

The company's platform focused on engineering psychedelic drugs. It has produced an extensive library of novel, analytically pure compounds that are nearing advancement into human trials. CaaMTech, Inc. uses the latest laboratory and computational technologies to drive the research and development of novel psychedelic drugs.

The company plans to use its Series A funding to support its cross-disciplinary science program, expand its leadership team, and advance its foremost drug development candidates into human trials.

## Funding rounds

- Series A, Sep 8, 2021, $22M — Noetic Fund

## Investors

- Noetic Fund (https://capitalatlas.ai/funds/noetic-fund) — Series A